Ilander, M
Olsson-Strömberg, U
Schlums, H
Guilhot, J
Brück, O
Lähteenmäki, H
Kasanen, T
Koskenvesa, P
Söderlund, S
Höglund, M
Markevärn, B
Själander, A
Lotfi, K
Dreimane, A
Lübking, A
Holm, E
Björeman, M
Lehmann, S
Stenke, L
Ohm, L
Gedde-Dahl, T
Majeed, W
Ehrencrona, H http://orcid.org/0000-0002-5589-3622
Koskela, S
Saussele, S
Mahon, F-X
Porkka, K
Hjorth-Hansen, H
Bryceson, Y T
Richter, J
Mustjoki, S
Article History
Received: 24 August 2016
Revised: 21 October 2016
Accepted: 4 November 2016
First Online: 28 November 2016
Competing interests
: UOS has received honoraria from Ariad. PK has received honoraria from Novartis, BMS, Ariad and Pfizer. HE has received development grant from Novartis and travel grants form BMS and Novartis. HHjH has received honoraria from Novartis, Bristol-Myers Squibb and Ariad. JR has received honoraria and research funding from Novartis and Bristol-Myers Squibb and honoraria from Ariad. SM and KP have received honoraria and research funding from Novartis, Bristol-Myers Squibb, and Pfizer. SM has received research funding from Ariad. The remaning authors declare no conflict of interest.